Holen Sie sich die Stockscreener-App
0.8193
40.92%
0.2379
Handel nachbörslich:
.78
-0.0393
-4.80%
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with - GlobeNewswire
TNYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TNYA SEC FilingsTenaya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Update Report: Is Tenaya Therapeutics Inc in a long term uptrendJuly 2025 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 - Bitget
Biotech Tenaya Therapeutics to stream CEO chat from Miami conference - Stock Titan
Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday - MarketBeat
Tenaya Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Group Gp Lp Column III Sells 3,511,826 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock - MarketBeat
Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells 658,440 Shares of Stock - MarketBeat
Venture firm Column Group (TNYA) details 23.1% Tenaya stake and stock sales - Stock Titan
Column Group funds trim Tenaya (TNYA) stake with 4.17M-share sale - Stock Titan
[144] Tenaya Therapeutics, Inc. SEC Filing - Stock Titan
Column Group files Form 144 for Tenaya Therapeutics (NASDAQ: TNYA) with share sale rows - Stock Titan
Major Tenaya Therapeutics Shareholder Makes Bold Move With Large Stock Sale - TipRanks
Column Group funds trim Tenaya Therapeutics (TNYA) with 829,734-share sale - Stock Titan
TNYATenaya Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) insider sells 1.905M and 161k shares - Stock Titan
Column Group III‑A sells large TNYA stake (02/2026) — TNYA - Stock Titan
What margin trends mean for Tenaya Therapeutics Inc. stockWall Street Watch & Entry Point Confirmation Alerts - mfd.ru
How Tenaya Therapeutics Inc. stock benefits from tech adoptionAnalyst Upgrade & Fast Moving Stock Watchlists - mfd.ru
Why Tenaya Therapeutics Inc. stock is favored by pension fundsShort Setup & Risk Controlled Daily Plans - mfd.ru
Bull Run: Is Tenaya Therapeutics Inc a speculative investmentQuarterly Market Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Form 4: Ali Faraz reports sale transactions in TNYA - Stock Titan
Planned sale of 5,160 TNYA shares disclosed in Rule 144 notice - Stock Titan
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Tenaya Therapeutics Inc. stock recession proofMarket Activity Recap & Fast Moving Stock Trade Plans - mfd.ru
TNYA PE Ratio & Valuation, Is TNYA Overvalued - Intellectia AI
Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells 4,056,573 Shares of Stock - MarketBeat
Group Gp Lp Column III Sells 343,717 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock - MarketBeat
Can Tenaya Therapeutics Inc generate free cash flowJuly 2025 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
Is Tenaya Therapeutics Inc. stock influenced by commodity pricesWeekly Profit Recap & Capital Efficient Trading Techniques - mfd.ru
Investment Review: Is Tenaya Therapeutics Inc. stock a safe buy before earningsDividend Hike & Trade Opportunity Analysis - mfd.ru
Tenaya Therapeutics (TNYA) holder files to sell 1,408,910 Rule 144 shares - Stock Titan
Breakouts Watch: Is Tenaya Therapeutics Inc a speculative investmentJuly 2025 Selloffs & Safe Entry Point Alerts - baoquankhu1.vn
Why retail investors favor Tenaya Therapeutics Inc. stockWeekly Trade Analysis & Weekly High Return Forecasts - mfd.ru
Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan By Investing.com - Investing.com South Africa
Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan - Investing.com Nigeria
Guidance Update: Is Waton Financial Limited stock a good pick for beginnersGap Down & Consistent Return Investment Signals - baoquankhu1.vn
Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan - TipRanks
Tenaya Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq bid-price warning hits Tenaya Therapeutics (Nasdaq: TNYA) as equity inducement pool grows - Stock Titan
Update Report: Is Tenaya Therapeutics Inc a speculative investmentJuly 2025 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Is Tenaya Therapeutics Inc. part of any ETF2025 Support & Resistance & Stepwise Swing Trade Plans - mfd.ru
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway - Yahoo Finance
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise - Sahm
How Does Tenaya Therapeutics' (TNYA) Extended Cash Runway Reframe Its Cardiac Gene Therapy Ambitions? - Yahoo Finance
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 - Finviz
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):